| DC1022 |
ABT-737
Featured
|
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively. |
|
| DC7353 |
ABT-751(E 7010)
Featured
|
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively. |
|
| DC4231 |
Linifanib (ABT-869)
Featured
|
ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
|
| DC11155 |
ABX-1431
Featured
|
ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL). |
|
| DC11183 |
ABX-1431 hydrochloride
Featured
|
ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL). |
|
| DC9660 |
Acalabrutinib(ACP196)
Featured
|
Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
|
| DC8760 |
Acalisib
Featured
|
Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM. |
|
| DC9986 |
Acebilustat(ZK322)
Featured
|
Acebilustat(ZK322) is a potent and selective leukotriene A4 hydrolase inhibitor. |
|
| DC10318 |
Acelarin
Featured
|
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine. |
|
| DC9900 |
Acetaminophen
Featured
|
Acetaminophen is a COX inhibitor for COX-1 and COX-2 with IC50 of 113.7 μM and 25.8 μM, respectively. |
|
| DC11512 |
Acrizanib
Featured
|
Acrizanib（LHA510） is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. |
|
| DC11439 |
Nemorexant
Featured
|
ACT-541468 is a dual orexin receptor antagonist. |
|
| DC10417 |
Acumapimod (BCT197)
Featured
|
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α. |
|
| DC8476 |
ACY-738
Featured
|
ACY-738 demonstrates inhibitory activity against recombinant HDAC6 with IC50 values of 1.7 nM, with respective average selectivity over class I HDACs being 100-fold. |
|
| DCAPI1273 |
Acyclovir (Aciclovir) |
Acyclovir (Aciclovir) |
|
| DC11886 |
Adavivint
Featured
|
Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro |
|
| DC7050 |
ADL5859 HCl
Featured
|
ADL5859 agonizes δ-opioid receptor with a 1000-fold selectivity than µ- or κ-opioid receptor with Ki of 32 nM and 37 nM, respectively.ADL5859 displays weak inhibitory activity at the hERG channel with an IC50 of 78 μM. The EC50 of ADL5859 against δ opioid |
|
| DC11097 |
ADX-102 (Reproxalap;NS-2)
Featured
|
ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain; DX-102 is a promising agent for the treatment of dry eye disease. |
|
| DC5113 |
AEE-788 (NVP-AEE788)
Featured
|
AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
|
| DC3164 |
BIBW2992-MA2 (Afatinib dimaleate)
Featured
|
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
|
| DC10513 |
AFN-1252(Debio 1452)
Featured
|
AFN-1252(Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 μg/ml. |
|
| DC7994 |
Afuresertib HCl
Featured
|
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). |
|
| DC8411 |
Afuresertib
Featured
|
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. |
|
| DC8051 |
AG-120 (Ivosidenib)
Featured
|
AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. |
|
| DC8374 |
AG-221(Enasidenib)
Featured
|
AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. |
|
| DC2096 |
AG490
Featured
|
AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
|
| DC10439 |
Vorasidenib (AG881)
Featured
|
AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2). |
|
| DC3171 |
Agomelatine |
Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. |
|
| DC8695 |
Akt1 and Akt2-IN-1 |
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. |
|
| DCAPI1467 |
Alcaftadine |
Alcaftadine |
|
